URGENT UPDATE: SINTX Technologies, Inc. has just signed a critical supply agreement with Evonik Corporation to advance the production of silicon nitride–PEEK (SiN/PEEK) compounds. This breakthrough enables immediate manufacturing of AI-assisted, 3D-printed patient-specific implants, set to revolutionize orthopedic and neurosurgical oncology treatments.
The announcement was made today, December 1, 2025, from SINTX’s headquarters in Salt Lake City, Utah. Under this agreement, Evonik will utilize its commercial-scale capabilities to produce SiN/PEEK compounds, allowing SINTX to respond rapidly to urgent physician requests for humanitarian-use vertebral body replacement (VBR) implants for patients who have undergone tumor resections in the spine.
“This agreement with Evonik marks a pivotal moment for SINTX and the field of patient-specific implants,” stated Eric K. Olson, Chairman, President & CEO of SINTX. The combination of Evonik’s polymer expertise and SINTX’s advanced biomaterials aims to deliver next-generation implants that address critical medical needs, particularly in trauma and oncology.
The SiN/PEEK compound is expected to provide significant advantages over traditional materials. It features antipathogenic surface characteristics, promotes bone integration, and enhances imaging capabilities during and after surgery—elements that are vital in complex, high-risk medical procedures.
Marc Knebel, head of Evonik’s Medical Devices & Systems segment, expressed enthusiasm for the collaboration, highlighting its potential to improve medical outcomes.
“This is another example of enabling innovation that EVONIK has delivered to improve medical outcomes,”
he said, emphasizing their commitment to quality and scalability in the production of regulated medical devices.
This supply agreement not only addresses immediate healthcare needs but also sets the stage for broader applications of the SiN/PEEK compound. SINTX is focused on regulatory clearances for both patient-matched and traditionally manufactured implantable devices, with an eye toward future market expansion.
The urgency of this development is underscored by the pressing need for customized implants that enhance fit and reduce infection risks. Dr. Ryan Bock, SINTX Chief Technology Officer, noted,
“We’re responding to real-world surgeon requests in oncology-related care.”
The company’s initial humanitarian efforts are directed towards trauma and oncology indications, addressing the needs of patients facing challenging surgical scenarios.
SINTX has established itself as a leader in high-performance biomaterials with nearly two decades of research and thousands of medical devices implanted since 2008. The agreement with Evonik is poised to further enhance SINTX’s capabilities, ensuring that they are at the forefront of medical innovation.
As this story develops, stakeholders in the medical community will be watching closely for the rollout of these advanced implants. The potential impact on patient care is profound, making this collaboration between SINTX and Evonik a significant milestone in the field of personalized medicine.
For further updates, stay tuned as SINTX Technologies and Evonik continue their groundbreaking work in the realm of patient-specific medical devices.
